Actively Recruiting
Diagnostic and Prognostic Value of New Quick Tests of Action Slowing in Stroke and in Cognitive Neurodegenerative Disease
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2026-05-13
129
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A large series of recent studies have documented the frequency of the slowing of the action in brain diseases, especially vascular and neurodegenerative diseases. In stroke, the predictive value of action slowing at the acute phase for predicting post-stroke functional outcome remains poorly investigated. In neurodegenerative diseases, the diagnostic relevance of the slowing at the prodromal stage remains unknown and this diagnostic requires new tests. Finally, in terms of anatomical determinants, few studies have studied the determinants of action slowing. The objectives of this project are to Determine the diagnostic and prognostic value of action slowing assessed with new quick tests in patients with acute stroke (Neurovascular Unit) and cognitive neurodegenerative disorders (Alzheimer Disease (AD), Lewy Body disease (LBD), Fronto Temporal lobar degeneration (FTLD), Cortico Basal Degeneration (CBD) and Progressive Supra Nuclear Palsy (PSNP)) and to define the lesion determinants with VBM and VLSM
CONDITIONS
Official Title
Diagnostic and Prognostic Value of New Quick Tests of Action Slowing in Stroke and in Cognitive Neurodegenerative Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients between 40 and 85 years old,
- French native language,
- Social Security affiliation.
- University Memory Clinic for: Mild severity disorder (MMSE> 19) or major severity disorder related to AD : Albert 2011 criteria ; McKhann 2011
- to MCL according to McKeith criteria
- to FTLD according to Rascovsky 2011 criteria
- BBD according to Armstrong's criteria
- related to PSP according to Höglinger criteria
You will not qualify if you...
- Mental retardation or guardianship
- Previously diagnosed dementia
- Other current or past brain condition
- severe head trauma
- epilepsy prior to stroke still requiring previous treatment
- Parkinson disease, multiple sclerosis...
- brain tumor or brain radiation therapy
- Current or past schizophrenia or psychosis
- Active or past psychiatric disorders requiring a stay> 2 days in a specialized environment
- Contra indication to MRI
- Comorbidity with life expectancy <1 year
- Comorbidity affecting cognition in particular:
- Alcohol (> 3 glasses / day) or history of alcohol withdrawal syndrome
- opiate or cocaine addiction or opiate withdrawal syndrome
- renal failure (dialysis or creatinine clearance <30)
- hepatic failure (spontaneous INR> 1.5 or PT <60%)
- respiratory failure requiring oxygen therapy
- heart failure (orthopnea> 2 pillows)
- persistent vigilance disturbances (NIHSS1a score ≤1)
- cancer with paraneoplastic syndrome
- treatment with gold salts, D Penicillamine or other treatment with cognitive effect
- Patient under guardianship or curators or private under public law
- Pregnant and / or lactating wom
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU Amiens
Amiens, France, 80054
Actively Recruiting
Research Team
M
Martine ROUSSEL, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here